Ziprasidone Market Size
The global Ziprasidone Market was valued at approximately USD 1.26 billion in 2025 and is anticipated to reach nearly USD 2.28 billion by 2033, expanding at a CAGR of 7.2% during the forecast period 2026–2033.Ziprasidone, commonly known as Geodon, is an atypical antipsychotic of the second generation that is used to treat schizophrenia and bipolar disorder, among other things. The pills include hydrochloride salt and ziprasidone hydrochloride, which rebalances dopamine and serotonin in the brain to improve mood and behavior.
As per DataM Intelligence, Ziprasidone Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Ziprasidone Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Ziprasidone Market in the United States and Canada produces the utmost share. Whereas the European Ziprasidone Market is projected to continue its presence globally during the period of 2023-2030.
Ziprasidone Market Summary and Scope
| Metrics | Details |
| Market CAGR | 7.2% |
| Segments Covered | By Route of Administration, By Application, By Distribution Channel and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Market Dynamics and Trends
The increasing prevalence of mental disorders worldwide is expected to drive market growth.
According to the World Health Organization, Schizophrenia causes psychosis, is associated with considerable disability and may affect all areas of life, including personal, family, social, educational, and occupational functioning. Schizophrenia affects around 24 million people globally or one in every 300 people (0.32 percent). Adults have a rate of 1 in 222 (0.45 percent). It is not as widespread as many other mental illnesses. Therefore, the demand for the medication has increased due to an increase in certain mental health conditions, which are largely treated with Ziprasidone.
Furthermore, the medicine is recommended because of the immediate effect visible when delivering the dose, resulting in immediate alleviation. Moreover, Dr. Reddy's announced the launch of Ziprasidone Mesylate on March 17, 2020, intending to make healthcare more affordable by giving value to the pharmacy. Thus, from the above statements, the market is expected to drive in the forecast period.
Side effects associated with ziprasidone are expected to hamper the market growth.
Ziprasidone is a medicine that increases the risk of weight gain, diabetes, and high cholesterol. Also, using ziprasidone is not recommended if the patient has a history of heart rhythm disorders, long QT syndrome, or uncontrolled heart failure, which diminishes the product's demand. Ziprasidone's low demand is due to side effects such as respiratory tract infections, extrapyramidal symptoms, akathisia, altered eyesight, dizziness, vomiting, headache, and nausea. Likewise, the availability of more effective alternatives like haloperidol, quetiapine, and aripiprazole diminishes market demand for ziprasidone. The metabolic syndrome health hazards associated with utilizing the product will hamper the market growth in the forecast period.
Industry Analysis
The ziprasidone market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.
Market Segmentation Analysis
Oral Capsules segment is expected to hold the largest market share in ziprasidone market
The oral capsules segment is expected to dominate in 2021. The segment benefits because the capsules have been approved by the US Food and Drug Administration (FDA) for long-term treatment of individuals with bipolar disorder due to their effectiveness and patient tolerability. The simplicity of long-term usage required due to the chronic nature of the sickness and the requirement of lesser doses of the medicine to be given at different times to improve the efficacy of the treatment also contribute to the demand. Oral capsules are less likely to cause an overdose. Oral capsules for Ziprasidone are less expensive than injections, making the medication more accessible and increasing demand. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
Market Geographical Share
North America region holds the largest market share in the global ziprasidone market
In 2021, North America accounted for the highest revenue share. The increasing prevalence of bipolar disorders, high adoption of ziprasidone drugs, product launches and acquisitions by the market key players and rising clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Institute of Mental Health, Bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the U.S. age 18 and older every year. Moreover, bipolar illness affects an equal number of men and women and affects people of all ages, races, ethnic groups, and social classes. Additionally, Upjohn, a part of Pfizer, announced the completion of the Phase 3 pediatric clinical trial for Geodon on November 10, 2020. (ziprasidone). The study looked at the efficacy and safety of ziprasidone in children and adolescents with bipolar I disorder. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.
Market Competitive Landscape
Major key players in the ziprasidone market are Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd., Wockhardt, Aurobindo Pharma USA.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
Product Portfolio:
GEODON (ziprasidone HCl): GEODON Capsules are indicated for treating schizophrenia in adults, acute treatment in adults as monotherapy of manic or mixed episodes associated with bipolar I disorder, and maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.
Recent Developments
- May 2026: Pfizer Inc. expanded post-marketing surveillance programs for ziprasidone formulations, supporting long-term schizophrenia and bipolar-disorder treatment safety monitoring initiatives globally.
- April 2026: Viatris Inc. strengthened generic ziprasidone production capabilities to improve psychiatric-drug accessibility and cost-effective mental-health treatment availability across emerging markets.
- March 2026: Teva Pharmaceutical Industries advanced development activities for improved ziprasidone dosage formulations supporting enhanced patient adherence and reduced adverse-effect management in psychiatric care.
- February 2026: U.S. Food and Drug Administration approved updated labeling recommendations for atypical antipsychotic therapies, supporting improved monitoring of cardiovascular and metabolic safety profiles in schizophrenia treatments.
- January 2026: Sun Pharmaceutical Industries Ltd. expanded global distribution networks for generic ziprasidone products supporting affordable access to antipsychotic medications in developing healthcare markets.
- December 2025: Aurobindo Pharma increased manufacturing investments for psychiatric-drug portfolios including ziprasidone capsules, supporting rising demand for mental-health therapeutics worldwide.
- November 2025: Dr. Reddy’s Laboratories strengthened neuropsychiatric generic-product pipelines supporting broader treatment accessibility for schizophrenia and bipolar-disorder patients internationally.
- October 2025: Hikma Pharmaceuticals enhanced injectable antipsychotic manufacturing capabilities supporting hospital-based psychiatric treatment programs and emergency mental-health care services.
- September 2025: World Health Organization emphasized expansion of affordable mental-health medicine access programs supporting wider adoption of essential antipsychotic therapies in low- and middle-income countries.
- August 2025: Lupin Limited expanded CNS-focused pharmaceutical research initiatives supporting improved antipsychotic drug formulations and next-generation psychiatric treatment development.
The global ziprasidone market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
